GSK acquires Chinese cancer drug in $750 million deal
British pharmaceutical giant GSK acquired global rights to a Chinese cancer drug.
Published 1sem1 sourceNotable
Lire en français
≈ 17s
The fact
The treatment, developed by Chimagen Biosciences, targets T-cells against cancer.
The deal highlights China's rise as a key player in biotechnology.
Click the link to read an article on the topic: